Posted by Michael Wonder on 04 Apr 2023
HUTCHMED completes rolling submission of NDA to US FDA for fruquintinib for the treatment of refractory metastatic colorectal cancer
31 March 2023 - NDA supported by data from global Phase 3 FRESCO-2 study in the US, Europe, Japan and Australia along with data from Phase 3 FRESCO study conducted in China.
HUTCHMED today announces that it completed the rolling submission of a new drug application to the US FDA for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1, -2 and -3, for the treatment of refractory metastatic colorectal cancer.
